KRISTINA TRAIL: Open Payments
NPI 1104590298 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,021 in 103 payments from 36 companies in 2025. Trend: 2023 $1,797 · 2024 $2,127 · 2025 $2,021
Food & beverage: $2,001Education: $20
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $199 |
| Janssen Biotech, Inc. | 12 | $193 |
| Celgene Corporation | 8 | $181 |
| Incyte Corporation | 6 | $150 |
| AstraZeneca Pharmaceuticals LP | 7 | $143 |
| Genentech USA, Inc. | 6 | $103 |
| Exelixis Inc. | 4 | $83 |
| TerSera Therapeutics LLC | 3 | $82 |
| Lilly USA, LLC | 4 | $82 |
| Merck Sharp & Dohme LLC | 3 | $61 |
Products named: REBLOZYL, MONJUVI, CABOMETYX, VERZENIO, CALQUENCE, ERLEADA, LYNPARZA, KEYTRUDA.
Industry payments across AL — which companies pay providers there.
